Exploring protective and pathogenic immune responses in the non-human primate model of tuberculosis

ObjectiveAlthough HCV is a major cause of chronic liver disease worldwide, there is currently no prophylactic vaccine for this virus. Thus, the development of an HCV vaccine that can induce both humoural and cellular immunity is urgently needed. To create an effective HCV vaccine, we evaluated neutralising antibody induction and cellular immune responses following the immunisation of a non-human primate model with cell culture-generated HCV (HCVcc).DesignTo accomplish this, 10 common marmosets were immunised with purified, inactivated HCVcc in combination with two different adjuvants: the classically used aluminum hydroxide (Alum) and the recently established adjuvant: CpG oligodeoxynucleotide (ODN) wrapped by schizophyllan (K3-SPG).ResultsThe coadministration of HCVcc with K3-SPG efficiently induced immune responses against HCV, as demonstrated by the production of antibodies with specific neutralising activity against chimaeric HCVcc with structural proteins from multiple HCV genotypes (1a, 1b, 2a and 3a). The induction of cellular immunity was also demonstrated by the production of interferon-γ mRNA in spleen cells following stimulation with the HCV core protein. These changes were not observed following immunisation with HCVcc/Alum preparation. No vaccination-related abnormalities were detected in any of the immunised animals.ConclusionsThe current preclinical study demonstrated that a vaccine included both HCVcc and K3-SPG induced humoural and cellular immunity in marmosets. Vaccination with this combination resulted in the production of antibodies exhibiting cross-neutralising activity against multiple HCV genotypes. Based on these findings, the vaccine created in this study represents a promising, potent and safe prophylactic option against HCV.

Download Full-text

Characterization of baboon fetal membranes: Evaluation as a non-human primate model of fetal membrane rupture

Journal of the Society for Gynecologic Investigation ◽

10.1016/s1071-5576(97)86699-3 ◽

1998 ◽

Vol 5 (1) ◽

pp. 192A-192A

Author(s):

J MCLAREN ◽

S BELL ◽

A FAALEABAS

Keyword(s):

Fetal Membrane ◽

Fetal Membranes ◽

Primate Model ◽

Membrane Rupture ◽

Fetal Membrane Rupture ◽

Human Primate

Download Full-text

Cardiac Pacing in a Chronically Instrumented Non-Human Primate Model During Centrifuge,

10.21236/ada316940 ◽

1996 ◽

Author(s):

S. C. Koenig ◽

Craig Reister ◽

J. Schtaub ◽

Gary Muniz ◽

Tim Fergusan

Keyword(s):

Cardiac Pacing ◽

Primate Model ◽

Human Primate

Download Full-text

Combined therapy of mesenchymal stem cells with a GLP-1 receptor agonist, liraglutide, on an inflammatory-mediated diabetic non-human primate model

Life Sciences ◽

10.1016/j.lfs.2021.119374 ◽

2021 ◽

Vol 276 ◽

pp. 119374

Author(s):

Roghayeh Navabi ◽

Babak Negahdari ◽

Ensiyeh Hajizadeh-Saffar ◽

Mostafa Hajinasrollah ◽

Yaser Jenab ◽

...

Keyword(s):

Stem Cells ◽

Mesenchymal Stem Cells ◽

Receptor Agonist ◽

Combined Therapy ◽

Primate Model ◽

Human Primate

Download Full-text

Neonatal Immune System Ontogeny: The Role of Maternal Microbiota and Associated Factors. How Might the Non-Human Primate Model Enlighten the Path?

Vaccines ◽

10.3390/vaccines9060584 ◽

2021 ◽

Vol 9 (6) ◽

pp. 584

Author(s):

Natalia Nunez ◽

Louis Réot ◽

Elisabeth Menu

Keyword(s):

Immune System ◽

Mode Of Delivery ◽

Microbial Colonization ◽

Therapeutic Interventions ◽

Primate Model ◽

Neonatal Immune System ◽

Gastrointestinal Colonization ◽

The Impact ◽

Human Primate

Interactions between the immune system and the microbiome play a crucial role on the human health. These interactions start in the prenatal period and are critical for the maturation of the immune system in newborns and infants. Several factors influence the composition of the infant’s microbiota and subsequently the development of the immune system. They include maternal infection, antibiotic treatment, environmental exposure, mode of delivery, breastfeeding, and food introduction. In this review, we focus on the ontogeny of the immune system and its association to microbial colonization from conception to food diversification. In this context, we give an overview of the mother–fetus interactions during pregnancy, the impact of the time of birth and the mode of delivery, the neonate gastrointestinal colonization and the role of breastfeeding, weaning, and food diversification. We further review the impact of the vaccination on the infant’s microbiota and the reciprocal case. Finally, we discuss several potential therapeutic interventions that might help to improve the newborn and infant’s health and their responses to vaccination. Throughout the review, we underline the main scientific questions that are left to be answered and how the non-human primate model could help enlighten the path.

Download Full-text

Combination therapy protects macaques against advanced Marburg virus disease

Nature Communications ◽

10.1038/s41467-021-22132-0 ◽

2021 ◽

Vol 12 (1) ◽

Author(s):

Robert W. Cross ◽

Zachary A. Bornholdt ◽

Abhishek N. Prasad ◽

Viktoriya Borisevich ◽

Krystle N. Agans ◽

...

Keyword(s):

Combination Therapy ◽

Rhesus Monkeys ◽

Viral Infections ◽

Virus Disease ◽

Marburg Virus ◽

Therapeutic Window ◽

Post Inoculation ◽

Primate Model ◽

Lethal Infection ◽

Human Primate

AbstractMonoclonal antibodies (mAbs) and remdesivir, a small-molecule antiviral, are promising monotherapies for many viruses, including members of the genera Marburgvirus and Ebolavirus (family Filoviridae), and more recently, SARS-CoV-2. One of the major challenges of acute viral infections is the treatment of advanced disease. Thus, extending the window of therapeutic intervention is critical. Here, we explore the benefit of combination therapy with a mAb and remdesivir in a non-human primate model of Marburg virus (MARV) disease. While rhesus monkeys are protected against lethal infection when treatment with either a human mAb (MR186-YTE; 100%), or remdesivir (80%), is initiated 5 days post-inoculation (dpi) with MARV, no animals survive when either treatment is initiated alone beginning 6 dpi. However, by combining MR186-YTE with remdesivir beginning 6 dpi, significant protection (80%) is achieved, thereby extending the therapeutic window. These results suggest value in exploring combination therapy in patients presenting with advanced filovirus disease.

Download Full-text